Goodwin Biotechnology Inc., a full service contract biomanufacturing company, and Hyprocell LLC, a provider of clinical cell line development services, have entered into a collaboration agreement to create a business model enabling customers to access their combined services.

The collaboration aims to enhance clinical development services by integrating cDNA synthesis, cloning into mammalian expression vector, transfection, clone selection and stable cell line development with cell banking, upstream/downstream process development and GMP manufacturing. According to the companies, customers will have a smooth transition from creating high producing stable cell lines to GMP manufacturing gram quantities of antibodies and recombinant proteins in a shorter time frame.

“Most of our customers are looking for one-stop shop type of CMO services and Hyprocell is a perfect partner to collaborate with to satisfy the market need,” said Bansi Bhan, chief financial officer, and interim chief executive officer at Goodwin Biotechnology. “Hyprocell has the cutting edge technology and yet offers small company innovation and flexibility that we are looking for in a successful collaboration.”

“We are excited about collaborating with Goodwin Bio, a company dedicated to delivering high quality clinical trial materials on time,” said Pitchai Sangan, Ph.D., president and chief executive officer of Hyprocell.”Our own Modular Flowcytometer is capable of isolating a single high producing cell out of millions of cells thus shortening the timeframe.Our Molecular Biology services integrated with Goodwin Bio’s superior cGMP capability will accelerate clinical development programs.”